Interleukin 4, Recombinant, Human (IL-4, B Cell Stimulatory Factor 1, BSF1, Binetrakin, HCGF, Hodgkin's Cell Growth Factor, IA Inducing Factor, Lymphocyte Stimulatory Factor 1, Macrophage Fusion Factor, Mast Cell Growth Factor 2, MCGF2, MFF, MGC79402, Pit

Interleukin-4 (IL-4) is a potent lymphoid cell growth factor which stimulates the growth and survivability of certain B cells and T cells. IL-4 is a pleiotropic cytokine that is produced by activated T cells, mast cells and basophils. IL-4 elicits many different biological responses, but has two dominant functions. The first is regulating differentiation of naive CD4+ T cell to the TH2 type. TH2 cells produce IL-4, IL-5, IL-10 and IL-13, which tend to favor a humoral immune response while suppressing a cell-mediated immune response controlled bu TH1 cells. The second is regulating IgE and IgG1 production by B cells. Recombinant IL-4 lacks all N-linked oligosaccharides to molecules highly overglycosylated, but all are fully biologically active. IL-4

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8426

Size

2ug

Form

Supplied as a sterile filtered, lyophilized protein. No additives.\n\nReconstitute in sterile dH2O to a concentration of 0.1-1mg/ml. This solution can then be diluted into other aqueous solutions.

Purity

(same/more than) 98% by SDS-PAGE and HPLCEndotoxin: (same/less than) 0.1ng/ug

References

US Biological application references: 1. Escobar, A. et al., (2005) Clin Exp Immunol. 142:555-568. 2. LOpez, M.N. et al., (2007) Investigative Ophthalmology and Visual Science 48:1219-1227. 1. Optimisation of the CT h4S bioassay for detection of human interleukin-4 secreted by mononuclear cells stimulated by phytohaemaglutinin or by human leukocyte antigen mismatched mixed lymphocyte culture. Petersen SL, Russell CA, Vindelov LL, Immunol Lett 2002 Oct 21;84(1):29-39\n2. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. Whitehead RP, Lew D, Weiss GR, Crawford ED, J Immunother 2002 Jul-Aug;25(4):352-8\n3. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. Ekerfelt C, Ernerudh J. J Immunol Methods 2002 Feb 1;260(1-2):55-67\n4. Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. Casolaro V, Keane-Myers AM, Steindler C, Ono SJ, J Biol Chem 2000 Nov 24;275(47):36605-11\n5. A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer. Davis ID, Maher DW, Green MD, Boyd AW, Growth Factors 2000;17(4):287-300\n6. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Okada H, Attanucci J, Pollack IF, Cancer Gene Ther 2000 Mar;7(3):486-94